The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2022 | INSURE: pooled analysis of patients with R/R multiple myeloma treated with IRd in the real-world
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares the results of INSURE, a pooled analysis of patients with relapsed/refractory (R/R) multiple myeloma treated with ixazomib, lenalidomide, and dexamethasone (IRd) in routine clinical practice. INSURE showed that progression-free survival (PFS) and time to next treatment data were comparable to what was reported in the TOURMALINE-MM1 study (NCT01564537). In addition, the study showed a significant benefit in PFS in frail patients. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
